Viridian (VRDN) | Financial Analysis & Statements
Viridian Therapeutics Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
132.0K
Operating Income
-122.7M
-92,991.67%
Net Income
-120.4M
-91,178.03%
EPS (Diluted)
$-1.08
Balance Sheet Metrics
Total Assets
899.4M
Total Liabilities
177.3M
Shareholders Equity
722.2M
Debt to Equity
0.25
Cash Flow Metrics
Operating Cash Flow
-105.4M
Free Cash Flow
-24.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Viridian Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 70.8M | 302.0K | 314.0K | 1.8M | 3.0M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 338.9M | 238.3M | 159.8M | 100.9M | 56.9M |
| Selling, General & Administrative | 95.3M | 61.1M | 95.0M | 35.2M | 25.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 434.2M | 299.3M | 254.8M | 136.1M | 82.7M |
| Operating Income | -363.4M | -299.0M | -254.4M | -134.3M | -79.7M |
| Operating Margin % | -512.9% | -99,018.2% | -81,035.0% | -7,579.2% | -2,690.8% |
| Non-Operating Items | |||||
| Interest Income | 27.4M | 32.1M | 18.6M | 4.9M | 318.0K |
| Interest Expense | 4.9M | 3.0M | 1.8M | 486.0K | 3.0K |
| Other Non-Operating Income | -1.7M | - | - | - | - |
| Pre-tax Income | -342.6M | -269.9M | -237.7M | -129.9M | -79.4M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -342.6M | -269.9M | -237.7M | -129.9M | -79.4M |
| Net Margin % | -483.6% | -89,387.1% | -75,711.5% | -7,329.2% | -2,680.2% |
| Key Metrics | |||||
| EBITDA | -337.2M | -266.4M | -235.4M | -129.1M | -79.3M |
| EPS (Basic) | $-3.32 | $-3.07 | $-5.31 | $-4.05 | $-6.66 |
| EPS (Diluted) | $-3.32 | $-3.07 | $-5.31 | $-4.05 | $-6.66 |
| Basic Shares Outstanding | 84803355 | 67885831 | 44755475 | 32087293 | 11918712 |
| Diluted Shares Outstanding | 84803355 | 67885831 | 44755475 | 32087293 | 11918712 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Viridian Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 212.4M | 99.6M | 102.8M | 155.6M | 42.3M |
| Short-term Investments | 662.3M | 618.0M | 374.5M | 269.0M | 154.7M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 19.6M | 20.9M | 9.0M | 6.5M | 2.7M |
| Total Current Assets | 894.2M | 738.5M | 486.5M | 431.2M | 200.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.7M | 3.3M | 2.8M | 2.8M | 2.5M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.5M | 501.0K | 604.0K | 982.0K | 1.5M |
| Total Non-Current Assets | 5.2M | 3.9M | 3.9M | 3.9M | 3.5M |
| Total Assets | 899.4M | 742.4M | 490.4M | 435.1M | 203.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 8.7M | 2.1M | 2.2M | 14.2M | 2.3M |
| Short-term Debt | 753.0K | 513.0K | 843.0K | 613.0K | 520.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | 100.0K | 100.0K | 100.0K | 100.0K |
| Total Current Liabilities | 70.7M | 47.9M | 26.6M | 33.3M | 13.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 49.9M | 20.6M | 20.2M | 4.6M | - |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 2.3M | 2.0M | 989.0K | 1.2M | 1.2M |
| Total Non-Current Liabilities | 106.6M | 22.9M | 21.8M | 6.7M | 2.4M |
| Total Liabilities | 177.3M | 70.8M | 48.4M | 40.0M | 16.0M |
| Equity | |||||
| Common Stock | 1.0M | 810.0K | 540.0K | 414.0K | 239.0K |
| Retained Earnings | -1.3B | -995.9M | -725.9M | -488.2M | -358.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 722.2M | 671.6M | 442.0M | 395.1M | 187.7M |
| Key Metrics | |||||
| Total Debt | 50.7M | 21.1M | 21.0M | 5.3M | 520.0K |
| Working Capital | 823.5M | 690.6M | 459.8M | 397.8M | 186.5M |
Balance Sheet Composition
Viridian Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -342.6M | -269.9M | -237.7M | -129.9M | -79.4M |
| Depreciation & Amortization | 460.0K | 540.0K | 522.0K | 255.0K | 120.0K |
| Stock-Based Compensation | 44.3M | 42.2M | 67.2M | 19.8M | 14.5M |
| Working Capital Changes | 6.6M | -259.0K | -12.3M | 11.6M | 1.8M |
| Operating Cash Flow | -286.8M | -227.0M | -175.8M | -98.0M | -55.5M |
| Investing Activities | |||||
| Capital Expenditures | -495.0K | -511.0K | -898.0K | -797.0K | -259.0K |
| Acquisitions | - | - | - | - | 0 |
| Investment Purchases | -579.3M | -695.1M | -407.9M | -223.3M | -188.4M |
| Investment Sales | 542.2M | 466.9M | 314.5M | 108.9M | 114.4M |
| Investing Cash Flow | -37.6M | -228.7M | -94.3M | -115.1M | -74.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 28.9M | 0 | 15.0M | 5.0M | 0 |
| Debt Repayment | - | - | - | - | 0 |
| Financing Cash Flow | 412.0M | 451.7M | 203.9M | 318.4M | 122.9M |
| Free Cash Flow | -276.9M | -232.8M | -185.1M | -94.6M | -54.9M |
| Net Change in Cash | 87.6M | -3.9M | -66.1M | 105.2M | -6.9M |
Cash Flow Trend
Viridian Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-4.20
Forward P/E
-5.89
Price to Book
2.46
Price to Sales
20.70
PEG Ratio
-0.13
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-95,643.18%
Return on Equity
-49.16%
Return on Assets
-27.67%
Financial Health
Current Ratio
12.65
Debt to Equity
7.28
Beta
1.16
Per Share Data
EPS (TTM)
$-3.32
Book Value per Share
$5.80
Revenue per Share
$0.84
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VRDN | 1.5B | -4.20 | 2.46 | -49.16% | 0.00% | 7.28 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






